drugset / Trial / NCT00697775
Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
RandomizedParallel-groupOpen-labelPrevention
Summary
In this study the safety and immunogenicity of 2 different formulations of the candidate HBV-MPL vaccine administered according to a 0, 6-month schedule were explored and compared to that of Engerix™-B in healthy adolescents aged 11 to 15
Timeline
- Start
- 1998-03
- Primary completion
- 1999-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine Formulation A | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine Formulation B | Vaccine | — | Intramuscular |